Trade FibroGen, Inc - FGEN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.23 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.025457% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003235% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
FibroGen Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 17.18 |
Open* | 18.65 |
1-Year Change* | 94.88% |
Day's Range* | 17.36 - 18.71 |
52 wk Range | 8.67-25.69 |
Average Volume (10 days) | 883.63K |
Average Volume (3 months) | 18.38M |
Market Cap | 1.69B |
P/E Ratio | -100.00K |
Shares Outstanding | 97.58M |
Revenue | 116.07M |
EPS | -3.27 |
Dividend (Yield %) | N/A |
Beta | 0.79 |
Next Earnings Date | Aug 7, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jun 2, 2023 | 17.79 | -0.94 | -5.02% | 18.73 | 19.05 | 17.34 |
Jun 1, 2023 | 17.18 | 0.22 | 1.30% | 16.96 | 17.59 | 16.70 |
May 31, 2023 | 17.16 | 0.15 | 0.88% | 17.01 | 17.61 | 16.72 |
May 30, 2023 | 17.04 | 0.47 | 2.84% | 16.57 | 17.33 | 16.46 |
May 26, 2023 | 16.65 | 0.03 | 0.18% | 16.62 | 16.80 | 16.33 |
May 25, 2023 | 16.82 | 0.16 | 0.96% | 16.66 | 16.91 | 16.44 |
May 24, 2023 | 16.90 | -0.05 | -0.29% | 16.95 | 17.33 | 16.51 |
May 23, 2023 | 17.27 | 0.06 | 0.35% | 17.21 | 18.03 | 16.99 |
May 22, 2023 | 17.16 | -0.14 | -0.81% | 17.30 | 18.02 | 16.96 |
May 19, 2023 | 17.49 | -0.07 | -0.40% | 17.56 | 18.07 | 17.20 |
May 18, 2023 | 17.53 | 0.01 | 0.06% | 17.52 | 17.89 | 17.29 |
May 17, 2023 | 17.77 | 0.80 | 4.71% | 16.97 | 17.86 | 16.92 |
May 16, 2023 | 17.40 | 0.25 | 1.46% | 17.15 | 17.51 | 17.08 |
May 15, 2023 | 17.58 | 0.46 | 2.69% | 17.12 | 17.91 | 17.03 |
May 12, 2023 | 17.31 | -0.11 | -0.63% | 17.42 | 17.66 | 17.09 |
May 11, 2023 | 17.48 | -0.12 | -0.68% | 17.60 | 18.00 | 17.38 |
May 10, 2023 | 17.65 | 0.25 | 1.44% | 17.40 | 17.84 | 17.17 |
May 9, 2023 | 17.30 | 1.25 | 7.79% | 16.05 | 17.89 | 15.97 |
May 8, 2023 | 17.61 | 0.58 | 3.41% | 17.03 | 17.73 | 16.55 |
May 5, 2023 | 17.29 | 1.14 | 7.06% | 16.15 | 17.55 | 15.83 |
FibroGen, Inc Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, June 7, 2023 | ||
Time (UTC) 15:00 | Country US
| Event FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
Friday, June 16, 2023 | ||
Time (UTC) 15:00 | Country US
| Event FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
Monday, August 7, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q2 2023 FibroGen Inc Earnings Release Q2 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
Monday, November 6, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 FibroGen Inc Earnings Release Q3 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
Revenue | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
Total Operating Expense | 441.759 | 523.839 | 368.199 | 345.891 | 299.651 |
Selling/General/Admin. Expenses, Total | 127.474 | 120.557 | 97.238 | 126.557 | 63.812 |
Research & Development | 296.791 | 387.043 | 252.924 | 209.265 | 235.839 |
Operating Income | -301.025 | -288.53 | -191.88 | -89.314 | -86.693 |
Interest Income (Expense), Net Non-Operating | 6.156 | -2.153 | 3.151 | 12.672 | 0.577 |
Net Income Before Taxes | -294.869 | -290.683 | -188.729 | -76.642 | -86.116 |
Net Income After Taxes | -295.227 | -291.03 | -189.089 | -76.97 | -86.42 |
Net Income Before Extra. Items | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
Net Income | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
Income Available to Common Excl. Extra. Items | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
Income Available to Common Incl. Extra. Items | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
Diluted Net Income | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
Diluted Weighted Average Shares | 93.582 | 92.349 | 89.854 | 86.633 | 84.062 |
Diluted EPS Excluding Extraordinary Items | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
Diluted Normalized EPS | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
Total Extraordinary Items | |||||
Cost of Revenue, Total | 20.28 | 12.871 | 8.869 | 1.147 | |
Gross Profit | 120.454 | 222.438 | 167.45 | 255.43 | |
Depreciation / Amortization | 0.587 | 4.639 | 10.369 | 10.307 | |
Other Operating Expenses, Total | -3.373 | -1.271 | -1.201 | -1.385 | |
Equity In Affiliates | 1.573 | 1.007 | -0.202 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total revenue | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
Revenue | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
Cost of Revenue, Total | 3.491 | 4.925 | 4.308 | 6.809 | 4.238 |
Gross Profit | 32.67 | 29.442 | 11.427 | 22.997 | 56.589 |
Total Operating Expense | 112.252 | 100.519 | 109.392 | 108.03 | 123.82 |
Selling/General/Admin. Expenses, Total | 34.275 | 33.966 | 29.902 | 30.258 | 30.564 |
Research & Development | 74.486 | 61.628 | 75.182 | 70.963 | 89.018 |
Other Operating Expenses, Total | |||||
Operating Income | -76.091 | -66.152 | -93.657 | -78.224 | -62.993 |
Interest Income (Expense), Net Non-Operating | -1.336 | -0.195 | 1.714 | 5.058 | -0.419 |
Net Income Before Taxes | -77.427 | -66.347 | -91.943 | -73.166 | -63.412 |
Net Income After Taxes | -77.501 | -66.455 | -92.057 | -73.189 | -63.525 |
Equity In Affiliates | 0.796 | 0.28 | 0.407 | 0.565 | 0.32 |
Net Income Before Extra. Items | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
Net Income | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
Income Available to Common Excl. Extra. Items | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
Income Available to Common Incl. Extra. Items | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
Diluted Net Income | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
Diluted Weighted Average Shares | 94.691 | 94.035 | 93.767 | 93.475 | 93.043 |
Diluted EPS Excluding Extraordinary Items | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 492.826 | 474.059 | 755.11 | 702.49 | 690.015 |
Cash and Short Term Investments | 422.008 | 405.19 | 686.537 | 533.757 | 621.402 |
Cash | 135.819 | 111.422 | 88.046 | 40.715 | 38.783 |
Cash & Equivalents | 19.881 | 59.801 | 590.347 | 85.551 | 50.475 |
Short Term Investments | 266.308 | 233.967 | 8.144 | 407.491 | 532.144 |
Total Receivables, Net | 16.299 | 25.401 | 41.883 | 153.665 | 63.684 |
Accounts Receivable - Trade, Net | 28.387 | 36.331 | 46.01 | 158.51 | 16.474 |
Prepaid Expenses | 9.73 | 7.383 | 8.353 | 6.464 | 4.929 |
Total Assets | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
Property/Plant/Equipment, Total - Net | 100.933 | 120.15 | 65.296 | 84.276 | 127.198 |
Property/Plant/Equipment, Total - Gross | 253.644 | 252.362 | 199.305 | 195.752 | 192.397 |
Accumulated Depreciation, Total | -152.711 | -132.212 | -134.009 | -111.476 | -65.199 |
Long Term Investments | 9.409 | 171.621 | 2.972 | 61.118 | 55.82 |
Other Long Term Assets, Total | 6.919 | 7.991 | 3.462 | 9.513 | 7.565 |
Total Current Liabilities | 273.562 | 225.497 | 163.187 | 102.745 | 89.033 |
Accounts Payable | 30.758 | 26.097 | 24.789 | 6.088 | 9.139 |
Accrued Expenses | 229.639 | 180.356 | 104.384 | 83.816 | 66.123 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 13.129 | 19.033 | 21.684 | 0.49 | 13.771 |
Total Liabilities | 631.534 | 564.675 | 404.662 | 341.262 | 371.399 |
Total Long Term Debt | 17.054 | 17.616 | 44.088 | 55.531 | 113.955 |
Long Term Debt | 16.917 | 17.613 | 18.697 | 16.78 | 16.798 |
Capital Lease Obligations | 0.137 | 0.003 | 25.391 | 38.751 | 97.157 |
Minority Interest | 19.967 | 19.967 | 19.271 | 19.271 | 19.271 |
Other Liabilities, Total | 320.951 | 292.403 | 169.441 | 163.715 | 149.14 |
Total Equity | -21.447 | 209.146 | 422.178 | 516.135 | 509.199 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.942 | 0.929 | 0.914 | 0.877 | 0.854 |
Additional Paid-In Capital | 1541.02 | 1476.41 | 1399.77 | 1300.72 | 1226.45 |
Retained Earnings (Accumulated Deficit) | -1557.69 | -1264.03 | -974.011 | -784.72 | -715.827 |
Other Equity, Total | -5.72 | -4.163 | -4.499 | -0.747 | -2.281 |
Total Liabilities & Shareholders’ Equity | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
Total Common Shares Outstanding | 94.1661 | 92.881 | 91.441 | 87.657 | 85.432 |
Total Inventory | 40.436 | 31.015 | 16.53 | 6.887 | |
Other Current Assets, Total | 4.353 | 5.07 | 1.807 | 1.717 | |
Current Port. of LT Debt/Capital Leases | 0.036 | 0.011 | 12.33 | 12.351 | |
Deferred Income Tax | 9.192 | 8.675 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 430.549 | 492.826 | 474.224 | 520.643 | 524.415 |
Cash and Short Term Investments | 355.949 | 422.008 | 408.52 | 438.133 | 428.075 |
Cash | 145.81 | 135.819 | 104.509 | 128.152 | 165.436 |
Cash & Equivalents | 42.74 | 19.881 | 51.451 | 39.606 | 20.46 |
Short Term Investments | 167.399 | 266.308 | 252.56 | 270.375 | 242.179 |
Total Receivables, Net | 17.654 | 16.299 | 15.328 | 33.573 | 43.883 |
Accounts Receivable - Trade, Net | 29.217 | 28.387 | 29.665 | 60.352 | 82.638 |
Total Inventory | 42.456 | 40.436 | 39.95 | 40.899 | 43.067 |
Prepaid Expenses | 14.49 | 9.73 | 10.426 | 8.038 | 9.39 |
Other Current Assets, Total | 4.353 | ||||
Total Assets | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
Property/Plant/Equipment, Total - Net | 95.367 | 100.933 | 105.19 | 109.159 | 114.871 |
Property/Plant/Equipment, Total - Gross | 253.644 | ||||
Accumulated Depreciation, Total | -152.711 | ||||
Long Term Investments | 5.884 | 9.409 | 22.411 | 50.414 | 97.643 |
Other Long Term Assets, Total | 6.744 | 6.919 | 7.012 | 6.573 | 9.005 |
Total Current Liabilities | 254.746 | 273.562 | 251.994 | 240.34 | 255.374 |
Accounts Payable | 71.282 | 30.758 | 19.323 | 29.36 | 36.353 |
Accrued Expenses | 166.969 | 229.639 | 224.577 | 202.681 | 211.518 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.036 | ||||
Other Current Liabilities, Total | 16.495 | 13.129 | 8.094 | 8.299 | 7.503 |
Total Liabilities | 587.396 | 631.534 | 582.531 | 583.009 | 587.886 |
Total Long Term Debt | 17.276 | 17.054 | 15.422 | 16.439 | 17.374 |
Long Term Debt | 17.276 | 16.917 | 15.422 | 16.439 | 17.374 |
Capital Lease Obligations | 0.137 | ||||
Deferred Income Tax | |||||
Minority Interest | 19.967 | 19.967 | 19.967 | 19.967 | 19.967 |
Other Liabilities, Total | 295.407 | 320.951 | 295.148 | 306.263 | 295.171 |
Total Equity | -48.852 | -21.447 | 26.306 | 103.78 | 158.048 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
Common Stock | 0.966 | 0.942 | 0.939 | 0.937 | 0.933 |
Additional Paid-In Capital | 1589.15 | 1541.02 | 1524.23 | 1509.64 | 1490.86 |
Retained Earnings (Accumulated Deficit) | -1634.39 | -1557.69 | -1491.51 | -1399.86 | -1327.24 |
Other Equity, Total | -4.57 | -5.72 | -7.346 | -6.93 | -6.505 |
Total Liabilities & Shareholders’ Equity | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
Total Common Shares Outstanding | 96.623 | 94.1661 | 93.936 | 93.733 | 93.289 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
Cash From Operating Activities | -145.933 | -82.232 | 81.602 | -78.705 | -76.144 |
Cash From Operating Activities | 10.604 | 14.809 | 22.047 | 21.454 | 6.562 |
Non-Cash Items | 66.687 | 132.899 | 74.216 | 62.47 | 52.112 |
Cash Interest Paid | 0.104 | 0.094 | 0.135 | 0.174 | 0.218 |
Changes in Working Capital | 70.43 | 60.083 | 174.63 | -85.659 | -48.398 |
Cash From Investing Activities | 89.116 | -426.972 | 452.487 | 120.018 | -522.123 |
Capital Expenditures | -38.741 | -30.186 | -3.994 | -5.762 | -8.02 |
Other Investing Cash Flow Items, Total | 127.857 | -396.786 | 456.481 | 125.78 | -514.103 |
Cash From Financing Activities | 46.776 | -0.563 | 13.343 | -4.3 | 13.875 |
Financing Cash Flow Items | -6.62 | -7.372 | -11.463 | -12.75 | -15.612 |
Issuance (Retirement) of Stock, Net | 53.934 | 12.701 | 37.829 | 20.778 | 29.847 |
Issuance (Retirement) of Debt, Net | -0.538 | -5.892 | -13.023 | -12.328 | -0.36 |
Foreign Exchange Effects | -5.482 | 2.597 | 4.695 | -0.005 | -0.008 |
Net Change in Cash | -15.523 | -507.17 | 552.127 | 37.008 | -584.4 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -76.705 | -293.654 | -227.479 | -135.829 | -63.205 |
Cash From Operating Activities | -101.591 | -145.933 | -93.42 | -41.54 | -8.476 |
Cash From Operating Activities | 2.965 | 10.604 | 7.914 | 5.235 | 2.584 |
Non-Cash Items | 18.148 | 66.687 | 49.928 | 34.441 | 17.77 |
Changes in Working Capital | -45.999 | 70.43 | 76.217 | 54.613 | 34.375 |
Cash From Investing Activities | 103.482 | 89.116 | 88.023 | 43.24 | 25.935 |
Capital Expenditures | -0.591 | -38.741 | -38.408 | -37.543 | -36.638 |
Other Investing Cash Flow Items, Total | 104.073 | 127.857 | 126.431 | 80.783 | 62.573 |
Cash From Financing Activities | 31.485 | 46.776 | -1.898 | -0.806 | -2.893 |
Financing Cash Flow Items | 0 | -6.62 | -4.562 | -3.361 | -2.974 |
Issuance (Retirement) of Stock, Net | 31.657 | 53.934 | 2.989 | 2.779 | 0.183 |
Issuance (Retirement) of Debt, Net | -0.172 | -0.538 | -0.325 | -0.224 | -0.102 |
Foreign Exchange Effects | -0.526 | -5.482 | -7.968 | -4.359 | 0.107 |
Net Change in Cash | 32.85 | -15.523 | -15.263 | -3.465 | 14.673 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
PRIMECAP Management Company | Investment Advisor | 14.4767 | 14126697 | 231619 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.0286 | 8810326 | -613439 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.2737 | 6122003 | 89685 | 2023-03-31 | LOW |
Astellas Pharma Inc | Corporation | 5.0915 | 4968367 | 0 | 2023-01-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.1772 | 4076167 | -188810 | 2023-03-31 | LOW |
Point72 Asset Management, L.P. | Hedge Fund | 3.5113 | 3426427 | -1355218 | 2023-03-31 | HIGH |
First Trust Advisors L.P. | Investment Advisor | 2.7884 | 2720975 | -254678 | 2023-03-31 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 2.7027 | 2637384 | 1262173 | 2023-03-31 | LOW |
Armistice Capital LLC | Hedge Fund | 2.3693 | 2312000 | -1552000 | 2023-03-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7703 | 1727545 | 70450 | 2023-03-31 | LOW |
Two Sigma Investments, LP | Hedge Fund | 1.7676 | 1724909 | 512435 | 2023-03-31 | HIGH |
Schroder Investment Management North America Inc. | Investment Advisor | 1.5138 | 1477161 | -246616 | 2023-03-31 | LOW |
Artisan Partners Limited Partnership | Investment Advisor | 1.3847 | 1351230 | 1351230 | 2023-03-31 | LOW |
Assenagon Asset Management S.A. | Investment Advisor | 1.3779 | 1344583 | 1344583 | 2023-03-31 | HIGH |
Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 1.1877 | 1159027 | -348288 | 2023-03-31 | MED |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.1157 | 1088768 | 593915 | 2023-03-31 | LOW |
Eventide Asset Management, LLC | Investment Advisor | 0.9838 | 960000 | 960000 | 2023-03-31 | MED |
Nuveen LLC | Pension Fund | 0.9185 | 896293 | 328958 | 2023-03-31 | LOW |
Adage Capital Management, L.P. | Hedge Fund | 0.8711 | 850000 | -1800000 | 2023-03-31 | LOW |
Eagle Asset Management, Inc. | Investment Advisor/Hedge Fund | 0.8488 | 828307 | -74825 | 2023-03-31 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group535K+
Traders
87K+
Active clients monthly
$113M+
Monthly investing volume
$64M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
FibroGen, Inc Company profile
About FibroGen Inc
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.
Industry: | Biotechnology & Medical Research (NEC) |
409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US
Income Statement
- Annual
- Quarterly
News

USD/TRY forecast: Turkish lira under pressure from high inflation and low rates
We look at some of the latest USD/TRY predictions as the Turkish lira hits record lows.
17:07, 1 June 2023
Nvidia’s 5-year stock forecast: Will the chipmaker remain at record highs?
Nvidia has been the winner of the AI race, being the first chip-maker to hit a $1tn market cap. Will the growth continue?
07:46, 31 May 2023
Google stock forecast 2023-2025
What is the outlook for the tech giant, following a tumultuous 2022?
18:02, 30 May 2023
USD forecast: DXY slides in risk-off market sentiment
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
16:10, 24 May 2023
Oil price forecast: Will WTI and Brent regain momentum in 2023?
Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.
11:38, 22 May 2023
Weekly Roundup: Tech stocks lead the way
US stocks push higher as risk appetite surges despite the uncertainty
13:39, 19 May 2023
USD/JPY continues to build higher towards 138
USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher
11:50, 17 May 2023People also watch
Still looking for a broker you can trust?
Join the 535.000+ traders worldwide that chose to trade with Capital.com